These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15058791

  • 1. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS, Finlay AY, Lewis JJ, Sumner MI.
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [Abstract] [Full Text] [Related]

  • 2. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
    Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY.
    Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
    [Abstract] [Full Text] [Related]

  • 3. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T, Furukawa F, Iwatsuki K, Matsue H, Shimada S, Takigawa M, Tokura Y.
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [Abstract] [Full Text] [Related]

  • 4. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
    Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, Norris PG, Friedmann PS, Graham-Brown RA, Dowd PM, Marks R, Sumner MJ.
    Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
    Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, Reitamo S, Ohannesson A, Mørk NJ, Clarke P, Pfister P, Paul C.
    Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB.
    Am J Clin Dermatol; 2010 Aug; 11(4):275-83. PubMed ID: 20513160
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R, Sánchez Regaña M, Massana J, Oliete R, Umbert P.
    J Dermatolog Treat; 2005 Aug; 16(4):238-41. PubMed ID: 16249146
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H, Abrams B, Bleehen SS, Bräutigam M, Burrows D, Ettelt MJ, Fry L, Happle R, Haustein UF, Ganslandt J, Jung EG, Knop J, Kühne KH, Mellein B, Mørk NJ, Rogers S, Schmidt AG, Schopf RE, Sumner M, Taube KM, Weidinger G, Wurdel C, Zahn E.
    Dermatology; 1998 Aug; 196(2):231-6. PubMed ID: 9568413
    [Abstract] [Full Text] [Related]

  • 14. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC.
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [Abstract] [Full Text] [Related]

  • 15. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A.
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [Abstract] [Full Text] [Related]

  • 16. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM, Bardazzi F, Tosti A, Varotti C.
    Acta Derm Venereol Suppl (Stockh); 1994 Oct; 186():90-1. PubMed ID: 8073851
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Oct; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH, Hartmann M, Toledo-Bahena ME, Gilbert M, Katsambas A, Yao R, Popmihajlov Z.
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.